Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Losordo, Douglas, M.D. |
---|---|
Information provided by: | Losordo, Douglas, M.D. |
ClinicalTrials.gov Identifier: | NCT00620048 |
The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction and heart failure symptoms.
Condition | Intervention | Phase |
---|---|---|
Myocardial Ischemia Congestive Heart Failure Cardiovascular Disease |
Biological: Autologous Stem Cells |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40% |
Estimated Enrollment: | 10 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 21 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |
Northwestern University | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Rita Vargos, RN 312-695-0006 rvargos@northwestern.edu | |
Contact: Sherrie Wolfe, RN, CCRC 312-926-3413 s-wolfe@northwestern.edu | |
Principal Investigator: Douglas W Losordo, MD |
Principal Investigator: | Douglas W. Losordo, M.D. | Northwestern University |
Responsible Party: | Northwestern University/Northwestern Memorial Hospital ( Director, Feinberg Cardiovascular Research Institute, Program in Cardiovascular Regenerative Medicine ) |
Study ID Numbers: | 11196-03 |
Study First Received: | February 7, 2008 |
Last Updated: | July 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00620048 History of Changes |
Health Authority: | United States: Food and Drug Administration |
heart stem Cells low EF heart attack cardiomyopathy |
congestive heart failure cardiovascular disease Heart Failure Low Ejection Fraction |
Heart Failure Heart Diseases Myocardial Ischemia Vascular Diseases |
Neovascularization, Pathologic Ischemia Cardiomyopathies Myocardial Infarction |
Heart Failure Pathologic Processes Heart Diseases Myocardial Ischemia |
Vascular Diseases Cardiovascular Diseases Ischemia |